Arbutus Biopharma Income Statement (2009-2026) | ABUS

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	2.33M	3.34M	3.21M	12.58M	14.24M	5.95M	6.25M	6.69M	4.65M	4.66M	2.15M	1.53M	1.73M	1.34M	1.57M	1.76M	10.74M	0.53M	1.05M	179.13M
Operating items
Amortization - Intangibles (Quarter)
Depreciation & Amortization - Total (Quarter)	0.44M	0.45M
Research & Development (Quarter)	15.80M	16.71M	19.21M	18.46M	22.94M	20.05M	22.95M	18.27M	17.69M	20.17M	17.56M	15.40M	15.55M	14.27M	8.81M	8.96M	5.50M	5.78M	5.01M	4.12M
Selling, General & Administrative (Quarter)	4.48M	4.18M	4.60M	4.89M	5.20M	3.49M	4.25M	5.55M	5.98M	5.84M	5.10M	5.31M	7.55M	4.54M	4.71M	5.83M	3.33M	3.04M	3.69M	5.89M
Restructuring Costs (Quarter)														3.62M	0.10M	12.37M	12.40M	0.10M	0.30M
Other Operating Expenses (Quarter)	0.26M	0.41M	0.19M	0.20M	0.21M	0.21M	1.61M	0.27M	-0.64M	0.20M	0.23M	0.18M	0.21M	0.34M	1.89M	0.30M	-11.97M	0.27M	-2.66M	0.21M
Operating Expenses (Quarter)	20.97M	21.75M	24.00M	23.55M	28.35M	23.76M	28.81M	24.10M	23.04M	26.22M	22.89M	20.89M	23.31M	22.78M	15.51M	27.46M	9.25M	9.19M	6.34M	10.22M
Operating Income (Quarter)	-18.64M	-18.41M	-20.80M	-10.97M	-14.11M	-17.81M	-22.56M	-17.41M	-18.39M	-21.56M	-20.75M	-19.36M	-21.58M	-21.44M	-13.93M	-25.70M	1.49M	-8.66M	-5.29M	168.91M
EBIT (Quarter)	-18.64M	-18.41M	-20.80M	-10.97M	-14.11M	-17.81M	-22.56M	-17.41M	-18.39M	-21.56M	-20.75M	-19.36M	-21.58M	-21.44M	-13.93M	-25.70M	1.49M	-8.66M	-5.29M	168.91M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)	0.03M	0.03M	0.03M	0.16M	0.40M	0.69M	0.94M	1.27M	1.46M	1.49M	1.47M	1.54M	1.83M	1.75M	1.46M	1.20M	1.04M	0.95M	0.88M	0.81M
Other Non Operating Income (Quarter)	-0.01M	-0.01M	0.01M		0.00M	-0.02M	-0.00M	0.00M	0.00M	0.01M	0.01M	-0.01M	-0.01M	0.01M	-0.03M	0.00M	0.02M	-0.01M	0.00M	-0.01M
Non Operating Income (Quarter)	-0.74M	-0.75M	-0.53M	-0.35M	-0.08M	0.24M	0.63M	1.07M	1.29M	1.45M	1.44M	1.49M	1.79M	1.72M	1.40M	1.17M	1.03M	0.92M	1.53M	0.79M
Net income details
EBT (Quarter)	-19.39M	-19.16M	-21.32M	-11.32M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M	169.71M
Tax Provisions (Quarter)				4.44M
Profit After Tax (Quarter)	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.88M	-19.80M	-19.72M	-12.53M	-24.53M	2.52M	-7.74M	-3.76M	169.69M
Equity Income (Quarter)
Income from Continuing Operations (Quarter)	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M	169.71M
Consolidated Net Income (Quarter)	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M	169.71M
Income towards Parent Company (Quarter)	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M	169.71M
Preferred Dividend Payments (Quarter)	3.27M	5.09M	0.57M
Net Income towards Common Stockholders (Quarter)	-22.65M	-24.25M	-21.89M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M	169.71M
Additional items
EPS (Basic) (Quarter)	-0.23	-0.24	-0.15	-0.11	-0.10	-0.12	-0.14	-0.10	-0.10	-0.12	-0.12	-0.10	-0.11	-0.10	-0.07	-0.13	0.01	-0.04	-0.01	0.88
EPS (Weighted Average and Diluted) (Quarter)	-0.23	-0.24	-0.15	-0.11	-0.10	-0.12	-0.14	-0.10	-0.10	-0.12	-0.12	-0.10	-0.11	-0.10	-0.07	-0.13	0.01	-0.04	-0.01	0.87
Shares Outstanding (Weighted Average) (Quarter)	96.87M	101.29M	106.24M	148.43M	148.75M	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	181.84M	184.24M	185.61M	190.71M	191.55M	191.35M	191.60M	193.77M
Shares Outstanding (Diluted Average) (Quarter)	96.87M	97.17M	106.24M	148.43M	148.75M	149.39M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	184.24M	185.61M	190.71M	191.13M	191.35M	191.60M	195.21M
EBITDA (Quarter)	-19.42M	-19.19M	-21.47M	-16.84M	-14.88M	-18.47M	-21.42M	-15.48M	-16.93M	-19.52M	-18.85M	-17.82M	-19.73M	-19.50M	-12.58M	-24.56M	2.50M	-7.68M	-3.73M	169.60M
Interest Expenses (Quarter)	0.76M	0.76M	0.56M	0.51M	0.48M	0.43M	0.31M	0.20M	0.17M	0.05M	0.04M	0.04M	0.03M	0.03M	0.03M	0.03M	0.03M	0.02M	0.02M	0.02M
Shares Outstanding (Quarter)	97.70M	110.26M	144.99M	148.73M	148.79M	152.71M	157.46M	165.13M	166.92M	167.70M	169.87M	180.19M	188.74M	189.44M	189.96M	191.48M	191.64M	191.95M	192.53M	196.95M
Tax Rate (Quarter)				-39.25

Research Tools

Developers

Arbutus Biopharma Income Statement (2009-2026) | ABUS

Research Tools

Developers

Arbutus Biopharma Income Statement (2009-2026) | ABUS

Create an account

Sign In

Reset Password